Reliability, validity, and clinical correlates of apathy in Parkinson's disease

Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis

BackgroundDespite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression.ObjectiveIdentification of differential aspects in disease progression in men and women with PD.MethodsLinear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin' sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms' trajectories in men and women. Men and women had similar age.ResultsOverall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (-0.159, 95%CI [-0.272, -0.046], p = 0.006), PDSS (-0.716, 95%CI [-1.229, -0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm).ConclusionsNext to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.

Positive Associations between the Personality Trait of Openness and Verbal Learning and Memory in Individuals with Parkinson's Disease: A Pilot Study

OBJECTIVE

Individuals with idiopathic Parkinson's disease (PD) often experience difficulties with verbal learning and memory, even in the absence of dementia. Higher levels of the personality trait of openness predict better learning and memory in other older adult populations, but openness's contributions in PD are unknown. Lower openness and alterations in openness's neural substrates in PD suggest that openness may have strong associations with memory in PD.

METHOD

We used the Big Five Inventory-2 (BFI-2) personality self-rating questionnaire and the Rey Auditory Verbal Learning Test (RAVLT) in a cross-sectional sample of 33 persons with PD (PwPD; 17 men), 26 healthy older adults (OA; 14 men), and 37 healthy younger adults (YA; 19 men). Correlation analysis examined relations between openness (BFI-2 open-mindedness) and verbal learning and memory (RAVLT performances). Correlation and regression analysis controlled for psychosocial and cognitive factors and examined possible moderators and mediators.

RESULTS

Significant, positive correlations between openness and RAVLT scores occurred in PwPD but not in OA or YA. Among PwPD, openness independently predicted most RAVLT scores in regression models. Its associations were not explained by PD duration, disease severity, disease stage, or sex. PwPD low in openness performed worse than OA. Among OA, older age predicted significantly more positive association between openness and memory.

CONCLUSIONS

Openness is positively associated with verbal memory in PwPD, as well as in healthy older adults (depending on age), with implications for the relevance of personality factors in cognition.

Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review

Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on quality of life not only for patients but also for caregivers. In recent years, there have been significant advances in the diagnosis and management of neuropsychiatric symptoms. However, there are still substantial gaps in therapeutic approaches and algorithms, with limited pharmacological and nonpharmacological treatment options currently available. One of the main reasons for this is the complex molecular and neural bases of these symptoms, which involve both dopaminergic and nondopaminergic neurotransmission systems and extend far beyond the nigrostriatal pathway. As a result, the drugs currently recommended for treating neuropsychiatric symptoms in PD are few and supported by limited evidence. In this context, the experience of the treating neurologist remains critical in selecting the most appropriate individualized therapy. The aim of this paper is to review the available therapeutic options and provide an overview of current research efforts, particularly those focusing on pharmacological treatments.

The Unseen Burden: Uncovering Shame and Its Determinants in Parkinson's Disease

BACKGROUND

Shame is frequent in Parkinson's disease (PD) and often overlooked.

OBJECTIVE

The aim was to assess factors associated with PD-related shame.

METHODS

PD-related shame was measured using the Shame and Embarrassment in PD (SPARK) scale in patients without cognitive impairment. Correlation between personal determinants (demographics, psychological traits [shame/guilt propensity, trait anxiety]), PD-related determinants (PD characteristics; motor, cognitive, and neuropsychiatric symptoms; medication; and health-related quality of life [QoL]), and SPARK was analyzed using multiple correlation analysis and generalized linear mixed models. To describe the cohort's response to shame, data-driven clustering based on SPARK was conducted, and clusters' associations with the determinants were analyzed.

RESULTS

Forty-seven PD patients were included. PD-related shame correlated with psychological traits (trait anxiety, shame, and guilt propensity), clinical symptoms (dyskinesia, state anxiety, depression, and apathy), and QoL. These determinants explained 79.3% of the total variance in the subsequent linear model analysis, with QoL and anxiety as the strongest covariates of shame. Apathy positively covaried with SPARK self-esteem subscale. Cluster analysis identified 3 patient groups. Highest-intensity shame cluster demonstrated elevated scores on both motor and nonmotor symptom-related shame and was associated with higher levels in anxiety, depression, and apathy, and poorer QoL. The remaining clusters showed a dissociation, with motor symptom-related shame predominating in one and nonmotor symptom-related shame in the other.

CONCLUSIONS

This study provides an in-depth understanding of shame, highlighting its multifactorial nature. Due to its impact on QoL, shame should be addressed in clinical practice through pharmacological/nonpharmacological interventions, targeting both shame and its modifiable determinants. Identifying distinct shame profiles underscores the need for tailored interventions.

Chronic apathy following a major depressive episode: What is it?

Distinguishing between neurological and psychiatric disorders can be challenging, particularly when apathy serves as the primary symptom, as it is a common manifestation in both neurodegenerative diseases and mood disorders. We present a cohort of 11 patients (7 females and 4 males) aged over 50 years (mean age 61.36 ± 5.870 SD). These individuals exhibited a prolonged and isolated apathy lasting over a year, without concurrent dysthymia, but with a history of a preceding major depressive episode. This article aims to comprehensively profile these patients and to explore whether this condition represents an unconventional clinical presentation of a well-established disorder or introduces a hitherto unrecognized clinical entity. Key characteristics of this group included the following: sustained use of one or more typically effective antidepressant medications during the depressive episode prior to the onset of apathy, with no improvement of apathy during follow-up; a partial response to a single dose of zolpidem; the presence of a dysexecutive syndrome, with minimal or absent neurological signs except for mild extrapyramidal signs in a subset of patients; and the identification of mesial frontal abnormalities in neuroimaging studies (involving atrophy and/or hypoperfusion and/or hypometabolism) in eight patients. Only two patients received a neurological diagnosis during follow-up, characterized by a DAT Scan suggestive of Parkinson's disease. The underlying cause of this syndrome remains uncertain, possibly multifactorial, and yet to be determined. To advance understanding and treatment of this condition, it is imperative for neurologists and psychiatrists to be aware of and recognize this syndrome.

Concurrent examination of gamma-stimulated variability in heart rate and auditory steady-state response in patients with major depressive, bipolar, and schizophrenia spectrum disorders

BACKGROUND

Heart rate variability (HRV), a well-established indicator of autonomic nervous system function, has been proposed as a clinical biomarker for psychiatric disorders. However, its potential is limited compared to electroencephalography (EEG) markers, possibly due to the influence of confounding factors such as cardiovascular functions. This suggests a need for autonomic metrics more specific to the central nervous system. This study investigated central autonomic control by applying 40 Hz auditory stimulation, which can transmit information beyond the auditory pathway to deep brain structures.

METHODS

A total of 165 participants, including individuals with major depressive disorder (MDD), bipolar disorder, schizophrenia spectrum disorders, and healthy controls, underwent HRV and EEG measurements during resting state and 20-Hz and 40-Hz auditory stimulation.

RESULTS

The 40-Hz stimulation led to a noticeable rise in the standard deviation of normal-to-normal intervals in HRV. There was a significant difference in low-, but not high-, frequency HRV among the diagnostic groups. Further exploratory analyses showed that during 40-Hz stimulation, patients with MDD experienced a larger decrease in low-frequency HRV compared to healthy individuals. In line with previous findings, patients with schizophrenia spectrum disorders showed a significant reduction in 40-Hz auditory steady-state response and significantly reduced resting theta.

CONCLUSIONS

These findings propose a novel metric, gamma (40-Hz) stimulated HRV, as a potential biomarker for impaired autonomic activation in MDD. Beyond the conventional framework, the combined approach of HRV and EEG using 40-Hz auditory stimulation may yield a series of biomarkers indicative of divergent brain functions between mood and psychotic disorders.

The Association of Apathy With Incident Dementia: A Multiple Mediation Analysis of Cardiovascular Risk Factors

OBJECTIVES

Despite established links between apathy, cardiovascular disease, and dementia, it remains unclear if cardiovascular risk factors (CVRF) play a mediating role in the association between apathy and dementia. If apathy increases dementia risk via lifestyle-related dementia risk factors, targeted lifestyle interventions could help high-risk individuals.

METHODS

We used data from the preDIVA study including 3303 individuals aged 70-78 years. Apathy was assessed using the geriatric depression scale, and CVRF (cardiovascular risk factors) (systolic blood pressure, cholesterol, diabetes, body mass index (BMI), smoking, and physical activity) were considered as potential mediators. Outcome was incident dementia during 12 years of follow-up. We assessed mediation using Multiple Mediation Analysis (MMA).

RESULTS

Of the association between apathy and dementia (HR 1.49 [95% CI 0.99-2.41]), 27% was mediated by physical inactivity, BMI and diabetes combined. Of this total, physical inactivity mediated 28% of the effect (HR 1.12, 95% CI 1.03-1.29), diabetes 9% of the effect (HR 1.04, 95% CI 1.02-1.10), and BMI counteracted these effects by -12% (HR 0.95, 95% CI 0.88-0.98).

CONCLUSION

The relationship between apathy and dementia is partly mediated by physical inactivity, BMI and diabetes. Apathy is an important clinical marker that signals the existence of potentially modifiable pathways, providing an opportunity for lifestyle interventions. To potentially reduce dementia risk via lifestyle modification in patients with apathy, a tailored approach should be taken to overcome the characterizing symptom of diminished motivation.

Non-motor Symptoms and Treatments in Parkinson's Disease

SYNOPSIS

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms. The non-motor features may precede the onset of motor symptoms and occur throughout all stages of PD. The non-motor symptoms reflect multisystem involvement of the central and peripheral nervous systems, multiple neurotransmitters, and multiple pathologies. PD management necessitates a comprehensive approach to address non-motor symptoms, including pharmacologic and non-pharmacological interventions and often multiple different disciplines or specialists in the PD care team. This review article discusses symptoms and treatments for the non-motor symptoms of PD including those affecting mood, cognition, behavior, sleep, autonomic function, and sensory systems.

Motivational disturbances and cognitive effort-based decision-making in Parkinson's disease

BACKGROUND

Motivational disturbances, such as apathy and impulse control disorders (ICDs), frequently co-occur in patients with Parkinson's disease (PD). The assessment of these motivational disturbances has proven to be challenging due the absence of validated objective behavioral measures for evaluating motivation in older adults. This scenario may contribute to underdiagnosis. The present study aimed to investigate the clinical utility of a modified version of an existing effort-based decision-making task which required cognitive (e.g., working memory) instead of physical (e.g., finger tapping) effort.

METHODS

Ninety-five non-demented individuals (45-85 years of age) with idiopathic PD completed a cognitive screening measure, self-report questionnaires, and a cognitive adaptation of the Effort Expenditure for Rewards Task (COG-EEfRT), which is a multi-trial game where a participant can choose whether to expend greater effort for larger rewards which vary in magnitude and probability. Patients were classified as having clinically significant symptoms of apathy and/or an ICD based on recommended cut-off scores on the Apathy Scale (AS) and Questionnaire for Impulse Control Disorders in Parkinson's Disease - Rating Scale (QUIP-RS). The methodological cutoffs defined two groups: Apathy (36.8 %), and ICD (48.4 %).

RESULTS

The level of effort expended by patients significantly predicted apathy and ICD status with high accuracy (88.2 % and 82.4 %, respectively), above and beyond age, levodopa equivalent dose and self-report measures of motivation. Additionally, we found that greater symptoms of apathy and ICD (i.e., negative urgency) were significantly correlated with patients choosing to expend greater effort. This result varied based on reward probability and outcome.

CONCLUSION

We offer preliminary evidence suggesting the clinical utility of the COG-EEfRT for identifying and quantifying motivational disturbances in PD. Additionally, anticipatory anhedonia and impulsive traits may be important predictors of cognitive effort-based decision-making. Compared to tasks requiring physical effort, the COG-EEfRT may be a more suitable tool for PD and perhaps for people with motor impairment.

Cholinergic basal forebrain atrophy and cortical alterations in Parkinson's disease with apathy

INTRODUCTION

Emerging evidences support the contribution of cholinergic deficiency to apathy in Parkinson's disease (PD). We aimed to ascertain the role of structural alterations of cholinergic basal forebrain (BF) and its innervated cortical regions in the pathogenesis of apathy in PD.

METHODS

Twenty-one PD patients with apathy (PD-A), 28 without apathy (PD-NA), and 20 healthy controls (HCs) were recruited in this study. Changes in subregional volumes of the BF were compared. Cortical thickness and local gyrification index (LGI) analysis were adopted to reveal the concomitant cortical alterations. The correlation with the severity of apathy and the diagnostic capacity were also assessed.

RESULTS

Compared to PD-NA and HCs groups, PD-A group showed excessively nucleus basalis of Meynert (NBM/Ch4) atrophy (p < 0.05 after Bonferroni correction), accompanied by cortical thinning and hypergyrification of the right entorhinal cortex (p < 0.001 after Bonferroni correction). Furthermore, regression analysis showing that the Ch4 volume was negatively associated with the severity of apathy in PD-A group (β = -23.198, T = -1.063, p = 0.039). All the above significant neuroimaging alterations showed good performance in identifying apathetic patients (p < 0.001).

CONCLUSION

Our findings highlighted that BF cholinergic degeneration driven by Ch4 atrophy may be involved in the pathogenesis of apathy in PD patients without dementia or depression.

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)

BACKGROUND

Parkinson disease (PD) is a chronic progressive neurodegenerative disorder leading to motor and non-motor impairment, often resulting in severe loss of quality of life. There are symptomatic treatments without effect on the progression of PD. A disease-modifying treatment that could ideally stop the neurodegenerative process is direly needed. Monosialotetrahexosylganglioside (GM1) is a promising molecule with neuroprotective effects in preclinical models of PD and has yielded encouraging results in patients with PD in a randomized placebo-controlled trial. Talineuren (TLN) is a liposomal formulation of GM1 that has been shown to cross the blood-brain barrier in animals. We assessed the safety and pharmacokinetics (PK) of TLN in patients with PD.

METHODS AND FINDINGS

We prospectively enrolled 12 patients with PD into a single-center, open-label phase I trial to assess the safety and tolerability of weekly infusions with TLN. The maximum suitable dose of TLN was determined by dose escalation in three patients. All three patients tolerated the predetermined maximal dose of 720 mg. Subsequently, these and nine additional patients received weekly infusions at the maximum suitable dose of 720 mg TLN over two months (1 patient stopped prematurely). PK were determined for the additional nine patients as a secondary outcome measure. Cmax was reached 4 h after infusion start for all but one participant, who reached Cmax after 1 h, while the median plasma half-life was reached at 12.6 h. All adverse events were continuously assessed as the primary objective and coded according to the Medical Dictionary for Regulatory Activities (MedDRA). Clinical manifestations of PD were assessed as secondary outcomes using the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), including a levodopa challenge test at baseline and end. In addition to weekly history taking, scales to measure mood, behavior, quality of life, sleepiness, non-motor symptoms of PD, and cognition were used as further secondary outcomes as well as assessing the Levodopa-Equivalent Daily Dose (LEDD). Overall, 304 adverse events (mean: 25.33; 6-75 events per patient) occurred, 267 of which were mild (mean: 22.25; 3-72 events per patient). 23 were considered related to the study treatment (0-8 events per patient). Very mild-to-severe acute infusion reactions at the second, third, or fourth administration of TLN within the first minutes of the infusion occurred in seven patients. All reported back or neck pain. Other acute infusion reactions were urticaria, plethora, nausea, and chest pain. These adverse reactions disappeared within minutes of stopping the infusion and did not recur when TLN administration was resumed at a very low rate. Beyond the fourth administration, infusions could be given at increased rates up to 370 ml/h, and no acute reaction occurred anymore. The mechanism of this acute infusion reaction remains unclear. Some patients reported mild dizziness for a few hours after TLN following many but not all administrations throughout the study. Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease -11.09; 95% Confidence Interval [CI]; -18, -4.1; p = 0.006), the Parkinson's disease Questionnaire-39 (PDQ-39) summary index (mean decrease -2.91; 95% CI; -4.4, -1.4; p = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease -4.27; 95% CI; -6.5, -2.1; p = 0.009). No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease -0.73; 95% CI; -2.1, 0.62; p = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; -2.6, 2.8; p > 0.999), Beck Depression Inventory (BDI) (mean decrease -1.27; 95% CI; -3.8, 1.3; p = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; -1.6, 2.4; p = 0.822). Dopaminergic medications remained stable during the study (LEDD mean increase 8.18; 95% CI; -7.7, 24; p = 0.423). While clinical improvements indicate a benefit associated with TLN treatment, the trial design does not allow for definite conclusions regarding efficacy. A randomized, placebo-controlled trial will be required to corroborate our exploratory findings.

CONCLUSION

TLN is safe and well-tolerated in general. This prospective phase I trial revealed non-allergic habituating acute infusion reactions at the second, third, or fourth treatment that can be prevented by a slower rate of infusion. Importantly, the exploratory results suggest a consistent improvement of signs and symptoms of PD.

TRIAL REGISTRATION

The NEON trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT04976127 and in the Swiss National Clinical Trials Portal (SNCTP000004631).

Predictors of Loneliness in Parkinson's Disease and Craniocervical Dystonia

BACKGROUND

Loneliness is a state in which an individual feels socially isolated due to deficiencies in the quantity or quality of social relationships and interaction. To date very little is known about loneliness in Parkinson's disease (PD) and focal/segmental craniocervical dystonia (FSCD).

OBJECTIVES

To explore whether level of loneliness is disease-specific by comparing PD, FCSD and healthy controls (HCs), and to define predictors of loneliness in both PD and FSCD.

METHODS

Eighty-two people with PD, 63 people with FSCD and 50 HC were surveyed. The UCLA Loneliness Scale was used to assess loneliness. Various non-motor symptoms, psychosocial variables and measures of subjective well-being were assessed and used as potential predictors of loneliness.

RESULTS

There was no significant difference in reported levels of loneliness between people with PD and matched HCs, and between people with PD and people with FSCD, but people with FSCD reported higher levels of loneliness than HCs (p = 0.018). Perceived stigma predicted loneliness in both disease groups (p < 0.001). Additionally, non-motor symptoms (p = 0.006), lack of optimism (p = 0.015) and practical social support (p = 0.006) predicted loneliness in people with PD. Patients with PD and FSCD with higher perceived stigma levels felt lonelier (p < 0.001), as did female patients with PD (p = 0.004), younger patients with FSCD (p = 0.007) and older patients with PD (p = 0.023).

CONCLUSIONS

We identified important predictors of loneliness in PD and FSCD. The identified age- and gender-specific differences in loneliness in people with PD and FSCD contribute to our better understanding of this complex and not yet fully understood concept.

Apathy in Parkinson's Disease: A Diagnostic Conundrum Explored in a Cohort Characterization Study

OBJECTIVE

Apathy is a prevalent neuropsychiatric feature of Parkinson's disease (PD), marked by reduced goal-directed behavior. Apathy is distinct from depression and significantly affects daily functioning and quality of life. Despite this, the DSM-5 does not acknowledge apathy as its own diagnostic category. The authors sought to examine how individuals with PD who score high on a self-report apathy scale are diagnostically classified by psychiatrists within a clinical setting.

METHODS

Fifty-five individuals with "pure apathy" were identified from a larger clinical convenience sample of 458 patients with PD. The pure-apathy group consisted of patients who scored above the clinical cutoff on a self-report measure of apathy but whose symptoms were below the cutoffs for depression and anxiety measures. These patients also received a standard clinical psychiatric evaluation using DSM-5 criteria. The authors examined the diagnoses provided by psychiatrists who were unaware of results of the mood scales.

RESULTS

More than half (53%) of the pure-apathy group had received no psychiatric diagnosis. The remainder had received the following diagnoses: anxiety (27%), depression (5%), comorbid depression and anxiety (5%), and other psychiatric diagnoses (9%). The most common anxiety diagnoses were unspecified or other specified anxiety disorders and generalized anxiety disorder. The most common depression diagnoses were unspecified or other specified depressive disorders.

CONCLUSIONS

This study highlights a gap in diagnosing psychiatric conditions in PD, specifically for individuals with primarily apathetic presentations. More than 50% of PD patients in the pure-apathy group had received no psychiatric diagnosis, possibly resulting in unmet clinical needs.

Improvement of apathy in early Parkinson's disease

Apathy is a disabling symptom in Parkinson's disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD.

Clinical and brain volumetric correlates of decreased DTI-ALPS, suggestive of local glymphatic dysfunction, in iRBD

Glymphatic alterations may underlie neurodegeneration in alpha-synucleinopathies. Reduced Diffusion-Tensor Imaging ALong the Perivascular Space (DTI-ALPS), a proxy of perivascular glymphatic activity, has been scarcely studied in isolated REM sleep behaviour disorder (iRBD), a prodromal synucleinopathy stage. Furthermore, its associations with clinical symptoms and brain structural abnormalities remain unexplored. We assessed the DTI-ALPS in sixty-two patients with iRBD and twenty-three healthy controls (HC), exploring its associations with clinical symptoms, cortical thickness and brain volumetric data. iRBD patients exhibited a lower DTI-ALPS and poorer odor identification, semantic fluency and processing speed relative to HC. The DTI-ALPS positively correlated with cognitive performance, olfactory function and amygdalar, hippocampal, brainstem and diencephalic volumes, and negatively with age in iRBD. Perivascular glymphatic activity is compromised in iRBD and is associated with brain atrophy and clinical risk factors of progression to alpha-synucleinopathies, supporting the potential of the DTI-ALPS index as an early imaging neurodegeneration marker.

Detecting neuropsychiatric fluctuations in Parkinson's Disease using patients' own words: the potential of large language models

Over the past decade, neuropsychiatric fluctuations in Parkinson's disease (PD) have been increasingly recognized for their impact on patients' quality of life. Speech, a complex function carrying motor, emotional, and cognitive information, offers potential insights into these fluctuations. While previous studies have focused on acoustic analysis to assess motor speech disorders reliably, the potential of linguistic patterns associated with neuropsychiatric fluctuations in PD remains unexplored. This study analyzed the content of spontaneous speech from 33 PD patients in ON and OFF medication states, using machine learning and large language models (LLMs) to predict medication states and a neuropsychiatric state score. The top-performing model, the LLM Gemma-2 (9B), achieved 98% accuracy in differentiating ON and OFF states and its predicted scores were highly correlated with actual scores (Spearman's ρ = 0.81). These methods could provide a more comprehensive assessment of PD treatment effects, allowing remote neuropsychiatric symptom monitoring via mobile devices.

Apathy in Alzheimer's disease: Eye movements characteristics and neurostructural basis

BACKGROUND

We sought to evaluate the characteristics of eye movements in Alzheimer's disease (AD) patients with apathy (AD-A) and their ability to identify AD-A and explore the shared neurostructure of eye movements and apathy.

METHODS

Total 32 normal controls, 36 AD-A, and 72 AD with no apathy (AD-NA) patients were recruited. Parameters of smooth pursuit, fixation, prosaccade, and antisaccade were compared among the three groups. Correlation analyses were conducted among apathy score, eye movement parameters, and gray matter volume (GMV) in AD patients. Receiver operating characteristic curves were used to determine the power of eye movement parameters to identify AD-A group.

RESULTS

AD-A group exhibited a longer start-up duration of smooth pursuit, latencies of gap and overlap prosaccades than AD-NA and normal control groups. In AD patients, apathy score was positively correlated with the latency of overlap prosaccade. The GMV of right pregenual anterior cingulate cortex (ACC) and left supracallosal ACC were negatively correlated with apathy score. Regions shared by apathy and the latency of overlap prosaccade included right pregenual ACC and left supracallosal ACC. The area under curve discriminated AD-A from AD-NA gropu by combining start-up duration, latencies of gap and overlap prosaccade, and demographic information was 0.812.

CONCLUSIONS

AD-A patients exhibit delayed initiation in eye movements, and the more prominent apathy indicates prolonged latency of overlap prosaccade in AD patients. Apathy and the latency of overlap prosaccade share a neurostructural basis in AD patients. Our results contribute to providing a new method for early identification and severity assessment for AD-A.

Development and Validation of the Parkinson's Disease Specific Anxiety Inventory (PDSAI)

BackgroundAnxiety is poorly recognized and inadequately treated in persons with Parkinson's disease (PD).ObjectiveThe present study aimed to develop and validate a new clinical screening and research outcome measure to identify triggers and manifestations of anxiety specific to PD, the Parkinson's disease Specific Anxiety Inventory (PDSAI).MethodData from PDSAI derived from 172 people with PD across Australia and the United States was used to assess the reliability and validity of the inventory. Construct validity was assessed.ResultsFrequency analyses revealed low rates of missing data across the 40 items. The inventory demonstrated high reliability (Cronbach's a = 0.93, split-half = 0.68) and mid to high concurrent validity between the PDSAI and (i) Hamilton Anxiety Scale (r = 0.51), (ii) Liebowitz Social Anxiety Scale (r = 0.697) and Parkinson's Anxiety Scale (r = 0.747).ConclusionsThe PDSAI is a valid and reliable tool designed to capture PD specific triggers and manifestations of anxiety in people with PD.

Altered Intra- and Inter-Network Resting-State Functional Connectivity is Associated with Neuropsychological Functioning and Clinical Symptoms in Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder

BACKGROUND

Isolated rapid-eye movement (REM) sleep behavior disorder (iRBD) is characterized by abnormal behaviors in REM sleep and is considered as a prodromal symptom of alpha-synucleinopathies. Resting-state functional magnetic resonance imaging (rsfMRI) studies have unveiled altered functional connectivity (rsFC) in patients with iRBD. However, the associations between intra- and inter-network rsFC with clinical symptoms and neuropsychological functioning in iRBD remain unclear.

OBJECTIVE

To characterize intra- and inter-network rsFC in iRBD patients using a data-driven approach and to assess its associations with clinical features and cognitive functioning.

METHODS

Forty-two patients with iRBD and 45 healthy controls (HC) underwent rsfMRI and comprehensive neuropsychological testing. Resting-state networks were characterized using independent component analyses. Group differences in intra- and inter-network rsFC and their associations with clinical and neuropsychological data were studied. A threshold of corrected P < 0.05 was used in all the analyses.

RESULTS

iRBD patients displayed lower intra-network rsFC within basal ganglia, visual, sensorimotor, and cerebellar networks, relative to HC. Mean rsFC strength within the basal ganglia network positively correlated with processing speed and negatively with the non-motor symptoms in iRBD patients. Reduced inter-network rsFC between sensorimotor and visual medial networks was observed in iRBD patients, which was associated with global cognitive status.

CONCLUSIONS

iRBD is characterized by both reductions in intra-network rsFC in cortical and subcortical networks and inter-network dysconnectivity between sensorimotor and visual networks. Abnormalities in intra- and inter-network rsFC are associated with cognitive performance and non-motor symptoms, suggesting the utility of both rsFC measures as imaging markers in prodromal alpha-synucleinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Subthalamic Deep Brain Stimulation: Mapping Non-Motor Outcomes to Structural Connections

In Parkinson's Disease (PD), deep brain stimulation of the subthalamic nucleus (STN-DBS) reliably improves motor symptoms, and the circuits mediating these effects have largely been identified. However, non-motor outcomes are more variable, and it remains unclear which specific brain circuits need to be modulated or avoided to improve them. Since numerous non-motor symptoms potentially respond to DBS, it is challenging to independently identify the circuits mediating each one of them. Data compression algorithms such as principal component analysis (PCA) may provide a powerful alternative. This study aimed at providing a proof of concept for this approach by mapping changes along extensive score batteries to a few anatomical fiber bundles and, in turn, estimating changes in individual scores based on stimulation of these tracts. Retrospective data from 56 patients with PD and bilateral STN-DBS was included. The patients had undergone comprehensive clinical assessments covering changes in appetitive behaviors, mood, anxiety, impulsivity, cognition, and empathy. PCA was implemented to identify the main dimensions of neuropsychiatric and neuropsychological outcomes. Using DBS fiber filtering, we identified the structural connections whose stimulation was associated with change along these dimensions. Then, estimates of individual symptom outcomes were derived based on the stimulation of these connections by inverting the PCA. Finally, changes along a specific non-motor score were estimated in an independent validation dataset (N = 68) using the tract model. Four principal components were retained, which could be interpreted to reflect (i) general non-motor improvement; (ii) improvement of mood and cognition and worsening of trait impulsivity; (iii) improvement of cognition; and (iv) improvement of empathy and worsening of impulsive-compulsive behaviors. Each component was associated with the stimulation of spatially segregated fiber bundles connecting regions of the frontal cortex with the subthalamic nucleus. The extent of stimulation of these tracts was able to explain significant amounts of variance in outcomes for individual symptoms in the original cohort (circular analysis), as well as in the rank of depression outcomes in the independent validation cohort. Our approach represents an innovative concept for mapping changes along extensive score batteries to a few anatomical fiber bundles and could pave the way toward personalized deep brain stimulation.

Impulse Control Disorders and Effort-Based Decision-Making in Parkinson's Disease Patients with Subthalamic Nucleus Deep Brain Stimulation

BACKGROUND

Impulse control disorders (ICD) are common side effects of dopaminergic treatment in Parkinson's disease (PD). Whereas some studies show a reduction in ICD after subthalamic nucleus deep brain stimulation (STN-DBS), others report worsening of ICD or impulsivity.

OBJECTIVE

The aim was to study ICD in the context of STN-DBS using an objective measure of decision-making.

METHODS

Ten PD patients performed an effort-based decision-making task alongside neuropsychiatric and cognitive evaluation before and 4 months after STN-DBS. Further, 33 PD patients underwent the same experimental procedures just once after an average 40 months of chronic STN-DBS. Participants were examined preoperatively in the medication on state and postoperatively in the medication on/stimulation ON state. Mixed linear models were used to assess the impact of ICD and STN-DBS on acceptance rate and decision time in the task while controlling for motor symptom burden, cognitive measures, and dopaminergic medication.

RESULTS

Results revealed an increased willingness to exert high levels of effort in return for reward in patients with ICD, but acceptance rate was not modulated by chronic STN-DBS. Further, ICD, cognitive processing speed, and STN-DBS were all identified as positive predictors for faster decision speed. ICD scores showed a tendency to improve 4 months after STN-DBS, without an increase in apathy scores.

CONCLUSIONS

Chronic STN-DBS and ICD facilitate effort-based decision-making by speeding up judgment. Furthermore, ICD enhances the willingness to exert high levels of effort for reward. Both STN-DBS and dopaminergic medication impact motivated behavior and should be titrated carefully to balance neuropsychiatric symptoms.

Cognitive Orientation to Daily Occupational Performance (CO-OP) in Parkinson's: Randomized Trial Findings

BACKGROUND

People with Parkinson's disease (PwPD) experience increasing disability due to progressive motor and non-motor symptoms. Comprehensive rehabilitation approaches are needed to maximize their daily functioning. CO-OP targets daily functioning and has established efficacy in populations with similar symptom profiles.

PURPOSE

To explore the potential of CO-OP for PwPD, a feasibility randomized controlled trial (RCT) was conducted.

METHODS

Consenting PwPD (n = 20) were recruited to a parallel group, assessor masked RCT. Following baseline assessment, participants were randomized to CO-OP (20 sessions:10-weeks) or a waitlist control (WLC; 0 sessions: 10 weeks). Goal attainment, functional and cognitive status, quality of life, self-efficacy, transfer, and maintenance were measured. Data were analyzed using descriptive statistics and multiple regression analysis.

RESULTS

Effort (M = 3.02/5) and enjoyment (M = 3.15/5) ratings; homework completion (M = 91%) and protocol adherence (M = 82%) indicate that CO-OP is feasible. CO-OP was superior to the WLC on Canadian Occupational Performance Measure (COPM) performance (p=<.001), COPM satisfaction (p=<.001), and Performance Quality Rating Scale (PQRS; p=<.001) but not the Goal Attainment Scale (GAS; p = .123).

CONCLUSIONS

Addressing a critical gap in Parkinson's disease management, findings suggest that CO-OP is implementable, feasible, and potentially beneficial for PwPD. Further research is warranted to further establish efficacy.

Effects of mental imagery training on cognitive function and brain connectivity in people with Parkinson's disease: A randomized pilot trial

Cognitive impairment is a debilitating problem in Parkinson's disease (PD) with no effective treatment. We developed a personalized mental imagery (MI) intervention focusing on goal-directed activities and examined its effect on everyday cognitive functioning and brain functional connectivity in people with PD in a pilot randomized controlled trial ( ClinicalTrials.gov identifier NCT05495997 ). Thirty nondemented people with PD were randomized to PD-MI and PD-Control groups. During the six-week training period, PD-MI received MI training and PD-Control received psychoeducation on cognitive health in PD. Participants underwent cognitive and functional MRI assessments at baseline, six weeks, and 18 weeks. The primary outcomes included changes in Neuro-QoL Cognitive Function (CF) survey scores and functional connectivity. The PD-MI compared to the PD-Control group showed (1) significant difference in Neuro-QoL-CF scores (F(1,26) = 6.802, p = 0.015) at six weeks which was not sustained at 18 weeks, (2) stronger connectivity between frontoparietal regions (T = 4.1, p = 0.009) during MI tasks at six weeks, and (3) weaker connectivity between visuospatial and motor regions at 18 weeks. Personalized MI training can be effective in facilitating cognitive preparedness for everyday tasks in people with PD. Its long-term effects and feasibility in cognitively impaired PD cohorts need further investigation.

Serotonergic dysfunction in patients with impulse control disorders in Parkinson's disease

Impulse control disorders (ICDs) are frequent and particularly distressing neuropsychiatric symptoms in patients with Parkinson's disease (PD) which are related to impaired behavioural inhibition. Multiple PET imaging studies indicate that striatal dopaminergic abnormalities contribute to hyperdopaminergic functioning in PD patients with ICD (PDICD+) and to the dysregulation of the limbic fronto-striatal networks which are critical for reward-related decision impulsivity. However, the serotonergic system is central to response inhibition and plays a critical role in neuropsychiatric symptoms in PD, but its role remains undetermined in PDICD. We hypothesized that PDICD+ patients exhibit serotonergic dysfunction within the cortico-striato-pallido-thalamic circuits involved in the inhibitory control of behaviour and decided to investigate the pre- and post-synaptic serotonergic innervation using two highly-specific PET tracers for the serotonin transporter (SERT) using [11C]DASB and the 5-HT2A receptor using [18F]altanserin. In this prospective, case-control, double-tracer PET study, we recruited 15 PDICD+ patients, 15 PDICD- patients and 15 healthy controls, matched for age and sex, and compared the availability of [11C]DASB and [18F]altanserin using permutation-based analysis. PDICD+ patients had one (n=9) or multiple ICDs (n=6), consisting in hypersexuality (n=8), compulsive eating (n=6), compulsive shopping (n=5) and pathological gambling (n=4) and were characterized by greater choice impulsivity (impaired delay discounting for monetary rewards) and greater urgency with more severe depressive and anxious symptoms. We demonstrate that PDICD+ patients had greater [11C]DASB binding in the posterior putamen and pallidum in comparison to PDICD- patients, corresponding to relatively preserved presynaptic SERT availability within the subcortical sensorimotor network involved in response inhibition. In addition, cortical [18F]altanserin binding was greater in PDICD+ patients in the bilateral supplementary motor area, precentral gyrus and right dorsolateral prefrontal cortex, involving the sensorimotor and associative networks which regulate behavioural inhibition. Furthermore, we show that pre- and post-synaptic serotonergic dysfunction subserving action versus decision impulsivity in PD patients specifically followed the distinctive functional organization of the sensorimotor and associative fronto-striatal networks. Altogether, we demonstrate that serotonergic dysfunction related to ICDs in PD specifically involve the sensorimotor and associative cortico-striato-pallido-thalamic circuits involved in inhibitory control. Thus, serotonergic dysfunction contributes to the mechanisms related to the vulnerability and development of ICDs in PD patients, beyond the known dopaminergic abnormalities in the limbic fronto-striatal circuit.

Reflexive and voluntary saccades as a proxy for bradykinesia and apathy in Parkinson's disease

BACKGROUND

Parkinson's disease (PD) encompasses motor (e.g., bradykinesia) and non-motor (e.g., apathy) symptoms.

OBJECTIVE

We aimed to use reflexive and voluntary saccades as a proxy for bradykinesia and apathy.

METHODS

Seventeen PD patients and thirteen controls (matched for age and educational level) were recruited. We assessed apathy using the Dimensional Apathy Scale (DAS) and bradykinesia using MDS-UPDRS III. Subjects were asked to fixate successively two green points (cues, 40° apart) alternating at 1 Hz. After 20 s, all stimuli disappeared, and participants were required to continue fixating on the previous locations of the cues at the same frequency for another 20 s. We measured the Maximal Amplitude (MA) (saccade amplitude from side to side) and its period. Linear mixed models assessed the effect of the group (patient/control), cue, DAS, and bradykinesia score.

RESULTS

Overall, the DAS was similarly correlated to the period (p = 0.0157) and the MA (p = 0.0002) in the absence of a cue. However, this correlation was significant only in the patient subgroup for the MA (p = 0.0005). In the absence of cue, bradykinesia was similarly correlated to the period (p = .0001) and the MA (p = 0.0004). However, the period was better correlated to bradykinesia than the DAS.

CONCLUSIONS

While the saccade period best correlates with bradykinesia, maximal amplitude in the absence of cue better reflects the severity of apathy. Our paradigm may be a promising objective biomarker for assessing bradykinesia and apathy in PD.

Cerebral blood flow and cognitive functioning in patients undergoing transcatheter aortic valve implantation

Background

Approximately one-third of patients with symptomatic severe aortic valve stenosis scheduled for transcatheter aortic valve implantation (TAVI) have some degree of cognitive impairment. The effect of TAVI on cardiac output, cerebral blood flow (CBF), and cognitive functioning has not been systematically studied.

Methods

CAPITA (NCT05481008) is a prospective longitudinal study assessing cerebral and cognitive outcomes in patients that underwent TAVI between August 2020 and October 2022. At baseline (<24 h before TAVI) and three-month follow-up, patients underwent echocardiography, brain magnetic resonance imaging (MRI), and multidomain neuropsychological assessment. Primary outcome measures were change in CBF (Δml/100 g/min on arterial spin labelling MRI) and change in global cognitive functioning (Δz-scores). Secondary outcomes included cardiac output (L/min), and white matter hyperintensities (mL, number). Differences were tested with paired t-test and associations were tested with linear mixed models.

Findings

A total of 148 patients (80.5 ± 5.7 years, 43% female) underwent TAVI. Three months after TAVI, cardiac output increased from 5.9 ± 1.4 L/min to 6.3 ± 1.4 L/min (mean difference 0.37, 95% CI 0.12-0.62, p = 0.004). CBF increased from 52.2 ± 14.5 mL/100 g/min to 55.9 ± 17.7 mL/100 g/min (mean difference 3.8, 95% CI 1.15-6.36, p = 0.005). Global cognitive functioning also increased from 0.02 ± 0.52 to 0.15 ± 0.49 (mean difference 0.13, 95% CI 0.06-0.20, p < 0.001) with most prominent increase in patients with worst baseline cognitive functioning. Patients with cognitive decline (22%), had a higher volume of new in white matter hyperintensities than patients with stable or improved cognition (78%): 1.26 ± 2.96, vs 0.29 ± 0.45, vs 0.31 ± 0.91 mL (p = 0.06).

Interpretation

In patients with severe symptomatic aortic valve stenosis undergoing TAVI, cardiac output, CBF, and cognitive functioning improved after three months.

Funding

The Heart-Brain Connection crossroad consortium of the Dutch Cardiovascular Alliance. The Netherlands CardioVascular Research Initiative: Dutch Heart Foundation (CVON 2018-28 & 2012-06 Heart Brain Connection).

A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington's disease

BACKGROUND

Cognitive impairment is a core feature of Huntington's disease (HD), yet no disease-modifying or symptomatic interventions have demonstrated efficacy in addressing these deficits. Non-pharmacological interventions, particularly cognitive training (CT), are promising options for maintaining neural plasticity, enhancing cognition, and improving emotional well-being.

METHODS

This 24-week, single-center, randomized, single-blind study evaluated the safety and efficacy of two cognitive rehabilitation strategies in early-to-middle-stage HD patients. Participants were randomized into a computerized cognitive training (CT; n = 13) intervention or a music therapy (MT; n = 16) intervention. A standard of care (SoC; n = 15) group with no active intervention was also involved. Weekly 45-min sessions were conducted. Baseline and endpoint assessments included measures of global cognition, functional, motor, and neuropsychiatric assessments, along with structural and functional neuroimaging.

RESULTS

Both CT and MT groups demonstrated significant improvements in primary and secondary cognitive endpoints, including global cognition an composite measures of disease severity. Regression analysis identified longitudinal cognitive score changes as independent predictors of the rate of atrophy in the caudate, putamen, and inferior frontal gyrus. Functional connectivity analysis showed distinct intervention-related effects: CT group exhibited increased connectivity between the central executive and sensorymotor networks, while MT group reduced aberrant connectivity between the central executive and the default-mode network.

CONCLUSION

This is the first randomized-controlled trial to evaluate two cognitive rehabilitation strategies in HD using multimodal neuroimaging. Both interventions were effective in improving cognition and modulating structural and functional brain changes in regions critical to HD. Trial Registration ClinicalTrials.gov (ID: NCT05769972).

A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy

BACKGROUND

Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive and neuropsychiatric disability in PSP is still missing.

OBJECTIVES

To create and validate a new scale for cognitive and neuropsychiatric impairment in PSP.

METHODS

The Short Cognitive and Neuropsychiatric (ShoCo) scale was developed containing five items (bradyphrenia, apathy, aphasia, dysexecution and disinhibition). Each item can be categorized into 0 = no deficit, 1 = mild deficit, 2 = moderate deficit and 3 = severe deficit. The total score includes 15 points, 0 meaning no deficit and 15 severe deficits. Cross-sectional and longitudinal data from 201 baseline and 71 follow up patients were analyzed.

RESULTS

Baseline ShoCo scale results were 5.9 ± 2.9. No significant differences between patients with Richardson syndrome (PSP-RS) and variants (vPSP) could be detected in the PSP-ShoCo scale scores (PSP-RS 6.1 ± 3.0, n = 160, vPSP 5.1 ± 2.6, n = 41, P = 0.057). The scale showed good correlation with established scores (eg, Montreal cognitive assessment r = -0.535, P = 0.001). The ShoCo scale showed significant annualized change within the PSP-RS patients (baseline 6.2 ± 2.9, follow up 6.9 ± 3.1, annualized diff. 1.0 ± 3.1, n = 57, P = 0.022).

CONCLUSIONS

The ShoCo scale seems a promising and valid tool to measure specific neuropsychological disabilities of PSP patients in clinical routine and research.

Effect of group exercise on quality of life for Parkinson disease: systematic review and meta-analysis

PURPOSE

Motor and non-motor symptoms can negatively affect quality of life (QoL) for people with Parkinson Disease (PD). Our purpose was to investigate the effects of group exercise (GE) compared to individual exercise (IE) and usual care (UC) on QoL for people with PD. A systematic review and meta-analysis were performed with randomized controlled trials that studied the effects of GE compared to IE and UC on QoL for people with PD.

MATERIALS AND METHODS

The systematic search was performed in EBSCO, PubMed, and Science Direct databases. Quality of methodology was assessed using the Cochrane GRADE approach. Thirteen studies met all inclusion criteria and were included in the analysis.

RESULTS

No significant difference was found on QoL between GE and IE; however, QoL was significantly improved with GE compared to UC. Results were based on low to moderate quality of evidence.

CONCLUSIONS

Based on low to moderate quality of evidence, GE has a similar effect on QoL when compared to IE and has a small and statistically significant effect when compared to UC, regardless of the patient reported outcome measure used or the total volume of exercise prescribed. GE may be an appropriate option for people with PD to improve their QoL.

A Comparison of In-Person and Telehealth Treatment Modalities using the SpeechVive Device

Telehealth is increasing popular as a treatment option for people with Parkinson disease (PD). The SpeechVive device is a wearable device that uses the Lombard effect to help patients speak more loudly, slowly, and clearly. This study sought to examine the effectiveness of the device to improve communication in people with PD, delivered over a telehealth modality as compared to in-person, using implementation science design. 66 people with PD were enrolled for 12 weeks with 34 choosing the in-person group and 32 in the telehealth group. Participants were assessed pre-, mid-, and post-treatment. Participants produced continuous speech samples on and off the device at each timepoint. Sound pressure level (SPL), utterance length, pause frequency, and total pause duration were measured. Psychosocial surveys were administered to evaluate the effects of treatment on depression, self-efficacy, and participation. The in-person group increased SPL when wearing the device while the telehealth group did not. Both groups paused less often while wearing the device. Utterance length increased post-treatment for the telehealth group, but not for the in-person group. An increase in communication participation ratings in the telehealth group, but not the in-person group, was the only significant change in the psychosocial metrics. The in-person group showed similar treatment effects as previous studies. The device was not as effective in the telehealth group. One limitation was data loss due to recording issues that impacted the telehealth group more than the in-person group.

Changes in sensor recorded activity patterns and neuropsychiatric symptoms after deep brain stimulation for Parkinson's disease: 5 case reports

BACKGROUND

Effects of subthalamic nucleus deep brain stimulation (STN-DBS) on neuropsychiatric symptoms of Parkinson's disease (PD) remain debated. Sensor technology might help to objectively assess behavioural changes after STN-DBS.

CASE PRESENTATION

5 PD patients were assessed 1 before and 5 months after STN-DBS with the Movement Disorders Society Unified Parkinson's Disease Rating Scale part III in the medication ON (plus postoperatively stimulation ON) condition, the Montreal Cognitive Assessment, the Questionnaire for Impulsive-Compulsive Behaviors in Parkinson's Disease Rating Scale present version, the Hospital Anxiety and Depression Scale and the Starkstein Apathy Scale. Steps taken per hour, nighttime spent in bed and time spent outside were monitored with a smartwatch and ambient sensors placed in patient homes for an average of 20 days pre- and postoperatively. Postoperative improvement in ICDs and concomitant anxious-depressive symptoms was observed in 3 patients and was accompanied by a decrease in steps taken per hour, as well as an increase in nighttime spent in bed. In the two patients without baseline ICDs, mild anxiety and apathy improved postoperatively, and no new neuropsychiatric symptoms occurred. Steps taken per hour did not decrease in these cases and nighttime spent in bed improved in one of the patients, but decreased in the other, who had experienced pain during OFF-phases at night before STN-DBS.

CONCLUSION

Changes in neuropsychiatric symptoms are associated with distinct activity patterns after STN-DBS, and wearable and ambient sensors may aid to capture those gradual shifts in behavior.

Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy

Sensing-based deep brain stimulation should optimally consider both the motor and neuropsychiatric domain to maximize quality of life of Parkinson's disease (PD) patients. Here we characterize the neurophysiological properties of the subthalamic nucleus (STN) in 69 PD patients using a newly established neurophysiological gradient metric and contextualize it with motor symptoms and apathy. We could evidence a STN power gradient that holds most of the spectral information between 5 and 30 Hz spanning along the dorsal-ventral axis. It shows elevated power in the sub-beta range (8-12 Hz) toward the ventral STN, and elevated dorsal beta power (16-24 Hz) indicative for the hemispheres contralateral to the more affected hemi-body side. The rigidity response to DBS was highest dorsally on the axis. Importantly, apathetic symptoms can be related to reduced ventral alpha power. In conclusion, the STN spectral gradient may inform about the motor and neuropsychiatric domain, supporting integrative closed-loop strategies.

From pleasure to punding: Distinct patterns of anhedonia and impulsivity linked to motivational disturbances in Parkinson disease

INTRODUCTION

Apathy and impulse control disorders (ICD) are common comorbid motivational syndromes in Parkinson disease (PD). This study aimed to determine if patients with these motivational disturbances exhibit different patterns of anhedonia and trait impulsivity.

METHODS

Sixty-four non-demented patients with PD completed questionnaires assessing apathy and ICD symptoms, which were used to classify participants into one of the following groups: apathy only, ICD only, both, and neither. Participants also completed multidimensional measures of anhedonia and trait impulsivity, which were compared across groups defined by motivational status.

RESULTS

Individuals with both apathy and ICD had significantly greater symptoms of positive and negative urgency than all other groups and had significantly greater consummatory anhedonia and lack of premeditation and perseverance than those with ICD only and neither. Patients with apathy only also reported significantly greater anticipatory anhedonia than those with ICD only and the neither group. There were no significant between-group differences in sensation seeking.

CONCLUSION

Distinct patterns of impulsivity and anhedonia characterize unique behavioral phenotypes of motivational disturbances in PD and may reflect important differences in the underlying neurobiological mechanisms. Clinicians should be aware that motivational disturbances may be more severe in cases where apathy co-occurs with one or more ICD.

Greater Apathy Associated With Selective Serotonin Reuptake Inhibitor Use in Parkinson's Disease

OBJECTIVE

Apathy, a motivational disorder, is common in Parkinson's disease (PD) and often misdiagnosed as depression. Use of selective serotonin reuptake inhibitors (SSRIs) has been associated with increased apathy in adolescents and adults with depression. Based on observations that serotonin may downregulate dopaminergic systems, we examined the relationship between apathy and SSRI use in individuals with PD.

METHODS

Medications, mood/motivation scales, and clinical data were collected from a convenience sample of 400 individuals with PD. Depression and apathy were measured using the Beck Depression Inventory-II (BDI-Il) and the Apathy Scale (AS). Antidepressant medications were grouped by mechanism type.

RESULTS

Of the 400 PD patients, 26% were on SSRIs. On standard mood/motivation scales, 38% of the sample exceeded clinical cut-offs for apathy and 28% for depression. Results of hierarchical regression analyses revealed that SSRIs were the only antidepressant that were significantly associated with higher apathy scores (β = .1, P = .02). Less education (β = -.1, P = .01) worse cognition (β = -.1, P = .01), and greater depressive symptoms (β = .5, P < .001) were also significant predictors of apathy.

CONCLUSION

These findings suggest that use of SSRIs, but not other antidepressants, is associated with greater apathy in PD. Given the interactive relationship between serotonin and dopamine, the current findings highlight the importance of considering apathy when determining which antidepressants to prescribe to individuals with PD. Similarly, switching a SSRI for an alternative antidepressant in individuals with PD who are apathetic may be a potential treatment for apathy that needs further study.

Constrained Emotional Sentence Production in Parkinson's Disease

PURPOSE

Deficits in the processing and production of emotional cues are well documented in the Parkinson's disease (PD) literature; however, few have ventured to explore how impairments may impact emotional language use in this population, particularly beyond the word level. Emotional language is an important multidimensional manner of communicating one's wants and needs; thus, the current study sought to explore how various aspects of language production may be impacted by the emotionality of a stimulus.

METHOD

Eighteen persons with PD and 22 healthy adults completed a constrained emotional sentence production task in which the affective target word was either a noun or a verb. Output was analyzed for fluency, grammaticality, completeness, and response initiation times. Cognitive (i.e., working memory [WM], inhibition, and switching) and mood (i.e., depression and apathy) measures were examined as factors influencing performance.

RESULTS

Individuals with PD produced fewer fluent responses than healthy controls. Furthermore, they had fewer grammatical responses in their production of negative sentences and exhibited reduced information completeness when producing sentences containing positive stimuli. Group differences could not be wholly attributed to individual differences in WM or apathy.

CONCLUSIONS

Our results support those of others that document language production deficits in individuals with PD above and beyond those impairments that can be explained by the select cognitive abilities explored here. Moreover, the emotionality of the topic may impact various aspects of communicative competence in persons with PD. For instance, disease processes associated with degeneration of neural substrates important for processing negative stimuli may also impact the grammaticality of productions containing negatively valenced content. Thus, it is important to consider how individuals in this population communicate during emotional circumstances.

SUPPLEMENTAL MATERIAL

https://doi.org/10.23641/asha.27289413.

Abnormal eye movements: relationship with clinical symptoms and predictive value for Alzheimer's disease

Background

Abnormal eye movements occur at the early stages of Alzheimer's disease (AD). However, the characteristics of abnormal eye movements of patients with AD and their relationship with clinical symptoms remain inconsistent, and their predictive value for diagnosing and monitoring the progression of AD remains unclear.

Methods

A total of 42 normal controls, 63 patients with mild cognitive impairment due to AD (AD-MCI), and 49 patients with dementia due to AD (AD-D) were recruited. Eye movements were assessed using the EyeKnow eye-tracking and analysis system. Cognitive function, neuropsychiatric symptoms, and activities of daily living were evaluated using various rating scales, and correlation analyses and receiver operating characteristic curves were performed.

Results

Patients with AD exhibited increased number of offsets and offset degrees, prolonged offset duration, and decreased accuracy in lateral fixation; reduced accuracy, prolonged saccadic duration, and decreased velocity in prosaccade; decreased accuracy and corrected rate, prolonged corrected antisaccadic duration, and reduced velocity in antisaccade; and reduced accuracy and increased inhibition failures in memory saccade. Eye movement parameters were correlated with global cognition and the cognitive domains of memory, language, attention, visuospatial ability, execution function, and activities of daily living. Subgroup analysis indicated that the associations between eye movements and clinical symptoms in patients with AD were influenced by disease severity and history of diabetes. In the AD-D and AD with diabetes groups, these associations diminished. Nevertheless, the associations persisted in the AD-MCI and AD without diabetes groups. The areas under the curves for predicting AD, AD-MCI, and AD-D were 0.835, 0.737, and 0.899, respectively (all p < 0.05).

Conclusion

Patients with AD exhibit distinct patterns of abnormal eye movements. Abnormal eye movements are significantly correlated with global cognition, multiple cognitive domains, and activities of daily living. Abnormal eye movements have a considerable predictive value for the diagnosis and progression of AD.

Quality of Life after Deep Brain Stimulation in Parkinson's Disease: Does the Target Matter?

BACKGROUND

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) is an accepted therapy for Parkinson's disease (PD) with disabling motor complications. For elderly patients with poorer cognition and postural instability, GPi has been proposed as the preferable DBS target based on expert opinion, arguing GPi-DBS may be less complicated by depression, apathy, worsened verbal fluency, and executive dysfunction, resulting in greater improvement in quality of life (QoL). However, data supporting such patient-tailored approach are lacking.

OBJECTIVES

The aims were to analyze whether the DBS target influences QoL in a PD cohort and a matched subgroup of frail patients with poor cognitive status and reduced postural stability, and whether other factors affect the QoL outcomes.

METHODS

In this retrospective study, we analyzed a single-center cohort of 138 PD patients who received bilateral STN-DBS (117) or GPi-DBS (21) using the mentioned approach for target selection. All patients underwent standardized clinical evaluations of motor- and nonmotor signs as well as QoL before and 1 year after surgery.

RESULTS

DBS of both targets improved motor signs, dyskinesias, and pain. QoL improved without significant difference between the targets, but with a trend for greater improvement across all QoL domains in favor of the STN, even in an STN subgroup matched to the GPi group.

CONCLUSION

Our results contradict the prevailing belief that GPi-DBS is superior in frail PD patients with cognitive decline and postural instability, questioning the proposed patient-tailored approach of DBS target selection. Further studies are needed for a data-driven approach.

Functional hearing impairment common in Parkinson's disease: Insights from a pilot study

INTRODUCTION

Hearing impairments in Parkinson's Disease (PD) have received limited attention in the past, possibly because PD patients often report no perceived hearing disability, yet negative consequences of hearing impairment might aggravate communication difficulties and social withdrawal.

OBJECTIVE

Our aim was to investigate functional hearing (speech in noise recognition) in PD and evaluate its relationship to neuropsychiatric symptoms, cognition and quality of life.

METHODS

Participants with PD were recruited in a tertiary movement disorder clinic. Demographic, audiological, neuropsychiatric and quality of life data were collected. Participants underwent pure tone audiometry (PTA) and Hearing in Noise test (HINT) as a part of their audiological evaluation.

RESULTS

A total of 29 participants (mean age: 65.8±8.3 years, M:F= 1.6:1, mean disease duration 5.2 ± 4.0 years) completed the study. All assessments were done in the ON state. 19/29 (65.5 %) participants had normal tone audiometry for age; functional hearing loss, however, was present in 17/29 (58.6 %) according to the HINT. 65 % (11/17) of the affected participants had a disease duration of <4 years. The majority (72.4 %) with poor functional hearing did not perceive any hearing impairment. Hearing deficits did not correlate with non-motor symptoms (NMS), including cognition or other quality of life measures.

CONCLUSIONS

Functional hearing loss is common in PD, often presents early in the disease and the majority of PD patients are unaware of their functional hearing loss. Its potential impact on cognition, communication and quality of life requires further investigation and tailored treatment.

Randomized crossover trial on motor and non-motor outcome of directional deep brain stimulation in Parkinson's disease

Deep brain stimulation (DBS) with electric field steering may avoid areas responsible for side effects. This prospective randomized cross-over trial compared omnidirectional (OS) and directional (DS) subthalamic DBS in 19 patients. Electromyographically measured rigidity was the primary outcome. Motor and non-motor scores were secondary outcomes. There were no significant differences between OS and DS. In the acute setting, both conditions improved motor scores compared to no stimulation. Motor symptoms improved after 3 weeks of OS relative to acute measurements, whereas they worsened under DS. The more ventral the active contact, and the less the motor improvement sweet spot was stimulated, the greater the benefit of DS over OS for executive function. Accurate OS of the dorsal subthalamic nucleus ensures motor and non-motor improvements. While DS can mitigate executive decline stemming from off-target stimulation, it may lead to worse motor outcomes. Larger, long-term studies are needed to confirm these findings. (Registration: subthalamic steering for therapy optimization in Parkinson's Disease ClinicalTrials.gov: NCT03548506, 2018-06-06).

Neuropsychiatric Manifestations of Degenerative Cerebellar Ataxia

BACKGROUND/OBJECTIVES

Degenerative cerebellar ataxias (DCA) present a group of complex neurological disorders primarily affecting the cerebellum and its pathways. Classic manifestations include motor symptoms of cerebellar ataxia. However, emerging evidence suggests that the cerebellum also plays a crucial role in various cognitive and emotional processes. The objective was to assess the psychiatric profile of a heterogeneous group of patients with degenerative cerebellar ataxia.

METHODS

Our sample comprised 107 participants diagnosed with cerebellar degenerative ataxia. All patients were clinically evaluated using SARA, INAS, and different neuropsychiatric scales (ACE-R, HAMA, HAMD, AS, and GAF).

RESULTS

The majority of patients had autosomal dominant ataxia (38.3%) followed by sporadic ataxia (32.7%) with an average age at the moment of diagnosis of 35.3 ± 16.23 years, while the mean duration of disease at the study beginning was 12.1 ± 9.9 years. Psychiatric disorders were present in 40 patients (37.4%), with dysthymia (14.2%), major depressive disorder (9.4%), and MDD with melancholic features (7.6%). The presence of MDD with melancholic features was statistically significantly correlated with a lower ACE-R total score (r = -0.223; p = 0.022), while dysthymia was statistically significantly associated with a shorter duration of the disease (r = -0.226; p = 0.020) and older age (r = 0.197; p = 0.043). Statistically significant differences were observed between MSA-C patients and those with sporadic ataxia (HDRS p < 0.001, HARS p < 0.001, Apathy Scale p = 0.003, and GAF p = 0.004).

CONCLUSIONS

Based on our findings, we can conclude that the degree of motor deficit has a significant impact on the development of psychiatric disorders, including depression, anxiety, and apathy. However, it is not the only factor, and the impact also depends on the type of DCA.

SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study

Introduction

Neuropsychiatric symptoms in particular impair health-related quality of life (QoL) of patients with Parkinson's disease and atypical Parkinsonian syndromes. For this reason, various scales have been developed for detection of neuropsychiatric symptoms, such as the Scale for evaluation of neuropsychiatric disorders in Parkinson's disease (SEND-PD).

Objective

First, the objective of this study was to explore the interrelation between the SEND-PD and clinical parameters in patients with Parkinson's disease and thus confirm its validity. In addition, the applicability in a well-defined cohort of patients with atypical Parkinsonian syndromes was investigated for the very first time.

Methods

A clinically well-defined cohort of 122 patients with Parkinson's disease (PD), 55 patients with Progressive Supranuclear Palsy (PSP) and 33 patients with Multiple System Atrophy (MSA) were analyzed. First, the SEND-PD was correlated with established disease-specific scores in patients with PD. Next, the results of the SEND-PD were compared between the different Parkinsonian syndromes.

Results

The SEND-PD showed a strong significant correlation with several scores, especially the UPDRS I (Rho = 0.655) and GDS-15 (Rho = 0.645). Depressive burden was significantly higher in MSA patients in comparison to the PD patient cohort (PD, 3.8 ± 3.3; MSA, 5.45 ± 3.87), while PSP patients showed significantly less psychotic (PD 1.6 ± 2.1; PSP 0.6 ± 0.9) and impulse control disorders (PD 0.3 ± 1.0; PSP 0.02 ± 0.1).

Conclusion

The SEND-PD is a useful, brief and highly applicable screening tool for neuropsychiatric symptoms in PD, but not in atypical Parkinsonism, as their unique neuropsychiatric symptom composition is not fully captured.

CADA-PRO: A Patient Questionnaire Measuring Key Cognitive, Motor, Emotional, and Behavioral Outcomes in CADASIL

BACKGROUND

Cerebral small vessel disease (cSVD) of ischemic type, either sporadic or genetic, as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), can impact the quality of daily life on various cognitive, motor, emotional, or behavioral aspects. No instrument has been developed to measure these outcomes from the patient's perspective. We thus aimed to develop and validate a patient-reported questionnaire.

METHODS

In a development study, 79 items were generated by consensus between patients, family representatives, and cSVD experts. A first sample of patients allowed assessing the feasibility (missing data, floor and ceiling effect, and acceptability), internal consistency, and dimensionality of a first set of items. Thereafter, in a validation study, we tested a reduced version of the item set in a larger sample to assess the feasibility, internal consistency, dimensionality, test-retest reliability, concurrent validity, and sensitivity to change.

RESULTS

The scale was developed in 44 patients with cSVD and validated in a second sample of 89 individuals (including 43 patients with CADASIL and 46 with another cSVD). The final CADASIL Patient-Reported Outcome scale comprised 18 items covering 4 categories of consequences (depression/anxiety, attention/executive functions, motor, and daily activities) of the disease. The proportion of missing data was low, and no item displayed a major floor or ceiling effect. Both the internal consistency and test-retest reliability were good (Cronbach alpha=0.95, intraclass correlation coefficient=0.88). In patients with CADASIL, CADASIL Patient-Reported Outcome scores correlated with the modified Rankin Scale, Starkstein Apathy Scale, Hospital Anxiety and Depression scale, Working Memory Index, and trail making test times. In patients with other cSVDs, CADASIL Patient-Reported Outcome correlated only with Hospital Anxiety and Depression scale and Starkstein Apathy Scale.

CONCLUSIONS

The CADASIL Patient-Reported Outcome may be an innovative instrument for measuring patient-reported outcomes in future cSVD trials. Full validation was obtained for its use in patients with CADASIL, but further improvement is needed for its application in other cSVDs.

Lille Apathy Rating Scale-Patient Version in Stroke Survivors: Psychometric Properties and Diagnostic Accuracy

OBJECTIVES

This study evaluated the factorial structure, psychometric properties, and diagnostic accuracy of the Persian version of the Lille Apathy Rating Scale-Patient version (LARS-P) in stroke survivors.

PARTICIPANTS

This study comprised 105 stroke survivors and 41 healthy controls.

METHODS AND SETTING

Exploratory factor analysis was used to determine the factors of the LARS-P. The acceptability, reliability, and validity of the LARS-P were also assessed. Agreement between the LARS-P and the Lille Apathy Rating Scale-informed version (LARS-I) was evaluated using the Bland-Altman plot. The diagnostic accuracy of the LARS-P was determined by categorizing stroke survivors into apathetic and nonapathetic groups based on the "diagnostic criteria of apathy."

RESULTS

The exploratory factor analysis showed 3 factors (action initiation and social life; novelty and motivation; and emotional and self-awareness), explaining 67.35% of the variance. Cronbach's alpha was 0.85 for between-items and 0.74 for between-subscales. Intra-class correlation coefficient (ICC)2,1 was >0.88 for test-retest and inter-rater reliability. The LARS-P showed moderate to strong correlations with the LARS-I and Neuropsychiatric Inventory-Apathy subscale (r = 0.70-0.82). In addition, the LARS-P had significant moderate correlations with 2 subscales of the Hospital Anxiety and Depression Scale, modified Rankin Scale, Barthel Index, and Lawton Instrumental Activities of Daily Living (r or ƿ = 0.47-0.63). There was a 96.19% agreement between LARS-P and LARS-I. The identified cutoff point (>17) for LARS-P exhibited 77.14% sensitivity and 90% specificity in diagnosing apathetic and nonapathetic stroke survivors.

CONCLUSIONS AND IMPLICATIONS

The LARS-P exhibits acceptable psychometric properties in stroke survivors, presenting a promising instrument for assessing apathy through a multidimensional framework.

Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review

Background

The concept of wellbeing is expansive and intricate, making it challenging to define precisely. Similarly, the instruments employed to assess wellbeing are complex and multifaceted. Therefore, it is more appropriate to refer to the notion of wellbeing as Health-Related Quality of Life (HRQoL), which is the central focus of many measures used to assess the feeling of wellbeing. This review aimed to identify the tools most commonly used to evaluate HRQoL in individuals with Parkinsonism-a group of movement disorders that negatively impact the quality of life due to the intricate interplay of symptoms, socio-demographic characteristics, and psychological factors. The main aim was to assess the psychometric properties of these measures in terms of validity and reliability.

Methods

A literature review was conducted, focusing on research related to the assessment of HRQoL in connection to symptoms of Parkinsonism. This review included all studies that examined HRQoL using evaluation scales, exams, or self-reported questionnaires. The literature review was conducted using the databases Scopus and Web of Science and the search engine PubMed to identify studies published between 1996 and 2023. Only records that assessed HRQoL in individuals with Parkinson's disease and Parkinsonism were selected for evaluation.

Results

A total of 393 records were examined, and eight tools were identified as the most frequently used in the evaluation of HRQoL.

Discussion

The results show a significant gap in knowledge regarding the latent structure and measurement invariance of HRQoL measurements, which may have a significant influence on the interpretation of test outcomes. Moreover, there is a lack of clear divergent validity between HRQoL assessments and other tests used as predictors of HRQoL. This could represent a significant limitation, affecting the construct and criterion validity of HRQoL measures.

Association between apathy and caregiver burden in patients with amyotrophic lateral sclerosis: a cross-sectional study

OBJECTIVES

To investigate the relationship among patients' apathy, cognitive impairment, depression, anxiety, and caregiver burden in amyotrophic lateral sclerosis (ALS).

DESIGN

A cross-sectional study design was used.

SETTING

The study was conducted at a tertiary hospital in Wuhan, Hubei, China.

PARTICIPANTS

A total of 109 patients with ALS and their caregivers were included.

OUTCOME MEASURES

Patients with ALS were screened using the Edinburgh Cognitive and Behavioural Screen, Beck Depression Inventory-II, Generalised Anxiety Disorder-7 and Apathy Scale to assess their cognition, depression, anxiety and apathy, respectively. The primary caregivers completed the Zarit Burden Interview. The association between apathy, cognitive impairment, depression, anxiety and caregiver burden was analysed using logistic regression. Mediation models were employed to investigate the mediating effect of patients' apathy on the relationship between depression/anxiety and caregiver burden.

RESULTS

Patients in the high caregiver burden group exhibited significantly higher levels of depression, anxiety and apathy compared with those in the low caregiver burden group (p<0.05). There was a positive association observed between caregiver burden and disease course (rs=0.198, p<0.05), depression (rs=0.189, p<0.05), anxiety (rs=0.257, p<0.05) and apathy (rs=0.388, p<0.05). There was a negative association between caregiver burden and the Revised ALS Functional Rating Scale (rs=-0.275, p<0.05). Apathy was an independent risk factor for higher caregiver burden (OR 1.121, 95% CI 1.041 to 1.206, p<0.05). Apathy fully mediated the relationship between depression and caregiver burden (β=0.35, 95% CI 0.16 to 0.54, p<0.05) while partially mediating the relationship between anxiety and caregiver burden (β=0.34, 95% CI 0.16 to 0.52, p<0.05).

CONCLUSIONS

Apathy, depression and anxiety exerted a detrimental impact on caregiver burden in individuals with ALS. Apathy played a mediating role in the relationship between depression and caregiver burden and between anxiety and caregiver burden. These findings underscore the importance of identifying apathy and developing interventions for its management within the context of ALS.

The Starkstein Apathy Scale-Italian Version: An Update

Apathy can manifest in various neuropsychiatric conditions, as well as in individuals who experience significant stressful life events or suffer from underlying internal medical conditions. The Starkstein Apathy Scale (SAS) is recognized as a reliable screening tool, besides being endorsed by the International Parkinson and Movement Disorder Society to assess apathy in patients with Parkinson's disease. Recently, the Italian version of this scale (SAS-I) has been introduced. Furthermore, normative data have been provided on a large sample of Italian healthy individuals. Here we present the official Italian translation of the SAS, along with clarifications regarding its administration. Also, we supply details concerning the scale's factorial structure, inter-item conditional associations and item performance by using EFA, Network analysis, and IRT modelling for polytomous items.

Real-time auditory feedback for improving gait and walking in people with Parkinson's disease: a pilot and feasibility trial

BACKGROUND

Technology is poised to bridge the gap between demand for therapies to improve gait in people with Parkinson's and available resources. A wearable sensor, Heel2Toe™, a small device that attaches to the side of the shoe and gives a sound each time the person starts their step with a strong heel strike, has been developed and pre-tested by a team at McGill University. The objective of this study was to estimate feasibility and efficacy potential of the Heel2Toe™ sensor in changing walking capacity and gait pattern in people with Parkinson's.

METHODS

A pilot study was carried out involving 27 people with Parkinson's randomized 2:1 to train with the Heel2Toe[TM] sensor and or to train with recommendations from a gait-related workbook.

RESULTS

A total of 21 completed the 3-month evaluation, 14 trained with the Heel2Toe[TM] sensor, and 7 trained with the workbook. Thirteen of 14 people in the Heel2Toe group improved over measurement error on the primary outcome, the 6-Minute Walk Test, (mean change 66.4 m) and 0 of the 7 in the Workbook group (mean change - 19.4 m): 4 of 14 in the Heel2Toe group made reliable change and 0 of 7 in the Workbook group. Improvements in walking distance were accompanied by improvements in gait quality. Forty percent of participants in the intervention group were strongly satisfied with their technology experience and an additional 37% were satisfied.

CONCLUSIONS

Despite some technological difficulties, feasibility and efficacy potential of the Heel2Toe sensor in improving gait in people with Parkinson's was supported.

Mixed effects models but not t-tests or linear regression detect progression of apathy in Parkinson's disease over seven years in a cohort: a comparative analysis

INTRODUCTION

While there is an interest in defining longitudinal change in people with chronic illness like Parkinson's disease (PD), statistical analysis of longitudinal data is not straightforward for clinical researchers. Here, we aim to demonstrate how the choice of statistical method may influence research outcomes, (e.g., progression in apathy), specifically the size of longitudinal effect estimates, in a cohort.

METHODS

In this retrospective longitudinal analysis of 802 people with typical Parkinson's disease in the Luxembourg Parkinson's study, we compared the mean apathy scores at visit 1 and visit 8 by means of the paired two-sided t-test. Additionally, we analysed the relationship between the visit numbers and the apathy score using linear regression and longitudinal two-level mixed effects models.

RESULTS

Mixed effects models were the only method able to detect progression of apathy over time. While the effects estimated for the group comparison and the linear regression were smaller with high p-values (+ 1.016/ 7 years, p = 0.107, -0.056/ 7 years, p = 0.897, respectively), effect estimates for the mixed effects models were positive with a very small p-value, indicating a significant increase in apathy symptoms by + 2.345/ 7 years (p < 0.001).

CONCLUSION

The inappropriate use of paired t-tests and linear regression to analyse longitudinal data can lead to underpowered analyses and an underestimation of longitudinal change. While mixed effects models are not without limitations and need to be altered to model the time sequence between the exposure and the outcome, they are worth considering for longitudinal data analyses. In case this is not possible, limitations of the analytical approach need to be discussed and taken into account in the interpretation.

Development and validation of the DBS-PS (Deep Brain Stimulation-Perception Scale): Assessing parkinsonian patients' expectations to prevent post-operative disappointment?

BACKGROUND

Recent literature suggests that taking into consideration and evaluating preoperative expectations of Parkinson's disease (PD) patients candidates to deep brain stimulation (DBS), can contribute to treatment effectiveness. However, few validated instruments investigating preoperative expectations are available. We present the development and validation of the DBS-PS (Deep Brain Stimulation - Perception Scale).

METHODS

The DBS-PS is an 11 questions self-administered scale, with answers rated on a 10-point Likert scale (1 completely false, 10 completely true). Items were generated on the basis of patient's interviews analyzed by an expert group and reached consensus. The scale is divided into three domains: expectations for PD, expectations for social-life and leisure, expectations for intimate life. Exploratory factor analysis (EFA) completed by item response theory (IRT) analysis was conducted to validate the theoretical structure of the DBS-PS.

RESULTS

64 PD patients aged 59.18 (SD = 5.74) years with PD diagnosed since 9.36 (SD = 4.09) years completed the DBS-PS preoperatively. EFA confirmed a 3 factors scale structure (eigenvalue >1) explaining 69% of variance (factor 1: 43%; factor 2: 17%; factor 3: 9%). Reliability (Cronbach's α: 0.714 for factor 1, 0.781 for factor 2, 0.889 for factor 3) and discriminant validity (Pearson coefficient r < 0.50) were satisfactory. IRT showed good model fit, preserved unidimensionality, but some local dependences were observed.

CONCLUSION

The DBS-PS shows satisfactory psychometric properties. It is easy to administer in routine practice with preoperative PD patients. It constitutes an interesting basis for cognitive restructuring before neurosurgery, by highlighting dysfunctional cognitions and measuring the benefits of cognitive restructuring therapy.